Zobrazeno 1 - 10 of 701 pro vyhledávání: '"J Mawdsley"'
1
P453 Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease
Autor: E Sharma, J Kotecha, A Akintimehin, S Ray, S H Anderson, J Mawdsley, P M Irving, M A Samaan
Publikováno v: Journal of Crohn's and Colitis. 16:i431-i433
Background Iron deficiency anaemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD). Ferric salts are the cheapest preparations at approximately £2 per treatment course compared to more costly alternative oral prep
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6463254b0fb67b9dca9437a355c13b15
https://doi.org/10.1093/ecco-jcc/jjab232.580
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Lower gastrointestinal bleeding in pregnancy: Differential diagnosis, assessment and management
Autor: Lisa Story, Anita Banerjee, J Mawdsley, S Rafique, B Singh, N Samadi
Publikováno v: Obstetric Medicine
Rectal bleeding is a common symptom experienced by pregnant women. Although the majority of cases are attributable to benign conditions such as haemorrhoids and anal fissures, other more serious diagnoses such as inflammatory bowel disease and malign
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da29394644c6d9955132fc1ef7ece3a4
https://doi.org/10.1177/1753495x20948300
Zobrazit plný text záznamu
6
P430 Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study
Autor: S Honap, E Sharma, S Ray, J Mawdsley, S Anderson, M Samaan, P Pavlidis, P Irving
Publikováno v: Journal of Crohn's and Colitis. 16:i414-i415
Background Tofacitinib is an oral small molecule inhibitor licensed for the treatment of ulcerative colitis (UC). Whilst real world data has been presented, outcomes beyond, 26 weeks are limited. The objective of this study was to assess the persiste
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c24ece19c59755a69c66a0747c6a02b
https://doi.org/10.1093/ecco-jcc/jjab232.557
Zobrazit plný text záznamu
7
P618 Pre-operative oral enteral nutritional optimisation for Crohn’s disease: A retrospective UK tertiary IBD centre cohort study
Autor: S Meade, K V Patel, R P Luber, D O’Hanlon, A Caracostea, P Pavlidis, S Honap, C Anandarajah, N Griffin, S Zeki, S Ray, J Mawdsley, M A Samaan, S H Anderson, A Darakhshan, K Adams, A Williams, J D Sanderson, M Lomer, P M Irving
Publikováno v: Journal of Crohn's and Colitis. 16:i545-i546
Background Low quality evidence suggests that pre-operative exclusive enteral nutrition (E/EN) can improve post-operative outcomes in patients with small bowel Crohn’s disease (CD). It is not standard practice in most centres. We aimed to test the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ab438165635562f97246c498e767376
https://doi.org/10.1093/ecco-jcc/jjab232.744
Zobrazit plný text záznamu
8
P567 Safety analysis of tofacitinib in ulcerative colitis: Real-world outcomes from a three-year UK observational cohort study
Autor: S Honap, E Sharma, S Ray, J Mawdsley, S Anderson, M Samaan, P Pavlidis, P Irving
Publikováno v: Journal of Crohn's and Colitis. 16:i510-i511
Background Serious adverse events (SAE), including venous thromboembolism (VTE) and major adverse cardiovascular events (MACE), have been reported in tofacitinib post-marketing trials. However, safety data extending beyond six months in the real worl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20706a6414f5f795762d124e775f6fe6
https://doi.org/10.1093/ecco-jcc/jjab232.693
Zobrazit plný text záznamu
9
P411 Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
Autor: A C Moore, D Russell, R Dart, S Dias, S Ghuman, B Petri, E Sharma, S Ray, S Anderson, J Mawdsley, P M Irving, M A Samaan
Publikováno v: Journal of Crohn's and Colitis. 16:i401-i402
Background Biosimilars have delivered significant cost savings, increasing access to biologics for many patients. While numerous studies have demonstrated no difference in efficacy between originators and biosimilars, the impact of switching between
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::747815233de0eb0079466a8f8221e879
https://doi.org/10.1093/ecco-jcc/jjab232.538
Zobrazit plný text záznamu
10
P422 How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
Autor: E Routledge, S Meade, E Sharma, S Zeki, S Ray, S Anderson, J Sanderson, J Mawdsley, M Samaan
Publikováno v: Journal of Crohn's and Colitis. 16:i408-i409
Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative provides recommendations on treatment targets for patients with Crohn’s disease (CD). The Simple Endoscopic Score for CD (SES-CD) is a validated endoscop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e8429ed4eae2d0d3f9505f32ae0e90
https://doi.org/10.1093/ecco-jcc/jjab232.549
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje